chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Palpable lymph node (B) in left post. occipital chain, <1 cm size - nontender, no redness or warmth; canker sores in mouth.
pt recvd vax; mid line at lt side of head all the way to shoulder; soreness, stiffness & nerves sensitive; 30nov94 starting to feel better;
Pt seen in ER after slipping and falling on blunt object. Cellulitis and contusion. Since tetanus status is greater than 5 years, offer to update Td accepted. Pt returned to ER 2 days post vax with complaints of left upper forearm and arm swollen, red, warm and sore.
pt ran low grade temp 2 day p/vax 19MAY93 had t102.6-rash on back & loss of appetite;
Patient reported to nurse who checked him that he was feeling lightheaded and had a headache after receiving the HPV, Menactra, and Influenza vaccines.  Headache was 10/10.  Vital signs were checked and initially normal.  Patient was assessed by physician and no focal deficits were noted.  He was advised to lie down after drinking water and given Tylenol for headache.  Upon reassessment patient reported decreased lightheadedness and headache now 9/10.  Vital signs rechecked and blood pressure was elevated, other vital signs stable.  Due to symptoms still being present advised further evaluation and assessment in ED.  Patient was subsequently seen there and given IV fluids and Reglan and Nephrology was consulted due to his blood pressure.  Examination remained unchanged from initial exam when first assessed after vaccination.
Pfizer 3/16/21, 4/6/21, 10/6/21. Positive on 3/10/22
Expired Havrix Administered; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 36-year-old male patient who received HAV (Havrix) (batch number 3F349, expiry date 9th August 2022) for prophylaxis.   On 3rd November 2022, the patient received Havrix. On 3rd November 2022, unknown after receiving Havrix, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.   Additional Information: GSK Receipt Date: 07-NOV-2022 Reporter's Comment: The reporter was a clinic manager. The reporter reported that the patient received Havrix vaccine which was expired on 09th August 2022. The vaccine administration facility was the same as primary reporter. The reporter consented to follow up. Additional supportive information: The patient received a Havrix which was already expired, which led to expired vaccine used. This case was 1 of 6 cases for the patient reported by same reporter.; Sender's Comments:  US-GSK-US2022162501:Same reporter US-GSK-US2022162503:Same reporter US-GSK-US2022162506:Same reporter US-GSK-US2022162508:Same reporter US-GSK-US2022162509:Same reporter
This case was reported by a consumer via call center representative and described the occurrence of swelling in a 69-year-old female patient who received SHINGRIX for prophylaxis. Previously administered products included SHINGRIX (did not have any side effects after the 1st dose of SHINGRIX in December 2018). On 9th March 2019, the patient received SHINGRIX. On 10th March 2019, 1 days after receiving SHINGRIX, the patient experienced swelling, tenderness, fever, arthralgia, chills, pain, walking difficulty and bedridden. On 13th March 2019, the outcome of the swelling, tenderness, fever, arthralgia, chills, pain, walking difficulty and bedridden were recovered/resolved. It was unknown if the reporter considered the swelling, tenderness, fever, arthralgia, chills, pain, walking difficulty and bedridden to be related to SHINGRIX. Additional details were provided as follows: The patient received SHINGRIX in the Left deltoid. The events were lasted for 3 days.
This spontaneous report as received from a registered nurse refers to multiple unspecified patients of unknown demographics. Information about patient's medical histories were not provided. On unknown dates, the patients were vaccinated with improperly stored doses of RECOMBIVAX HB (doses, frequency, routes of administration and lot # were not specified). Concomitant medication was not reported. No adverse effects were reported. No product quality complaint (PQC) was involved. Additional information has been requested.
This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 28 year-old female patient (not pregnant) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single and (Batch/Lot number: unknown) as dose 2, single for Covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PALPITATIONS (non-serious), outcome "not recovered", described as "Racing heart"; CHEST PAIN (non-serious), outcome "not recovered", described as "chest pains". No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
I was 6 weeks pregnant at the time of miscarriage on oct 29th. I went to ER with bleeding and was told I had lost the pregnancy. This means I became pregnant within the week I received the vaccine. EDD was June 27th.
This spontaneous report as received from a medical assistant refers to a patient of unknown age and gender. Concurrent conditions and medical history were not reported. On an unspecified date in December 2015, the patient was vaccinated with the second dose of GARDASIL 9 (Lot number, expiration date and route were not provided). Concomitant medications were not reported. The reporter stated that "today" on 08-SEP-2016, the patient would be administered the third dose of the GARDASIL 9 series, which was longer than the recommended time frame. No adverse effects reported. Additional information has been requested.
Pt erroneously received expired Pfizer dose on 12/1/21. Staff contacted Pfizer to inquire if lot of vaccines were still viable at time of vaccination. Following discussion with Mfr,  pt did not need to be revaccinated as Pfizer Mfr had stability data to support this excursion for 1 day post expiry from manufacturing data.
Vaccine given on 1-9-12. Fever started 1-19-12, blisters (pustules) occurred on 1-20-12.
He started with Crohn's flare up causing symptoms with fatigue and diarrhea. We changed his diet it progressed by September he lost 9 lbs. and experienced abdominal pain. The doctor prescribed him Cipro and increased dosage of Humira. By the end of October it started to subside. This is not his first Crohn's flare he has experienced this in the past therefore this was not a total shock.
feels like she is going to die/ does not feel well today; Fever; vomited; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (feels like she is going to die/ does not feel well today), PYREXIA (Fever) and VOMITING (vomited) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Heart rate high, Lung operation and Oophorectomy. Concurrent medical conditions included Breast cancer (Breast Cancer that traveled to her lungs) and Immunocompromised. Concomitant products included METOPROLOL, CLONAZEPAM (KLONOPIN), SERTRALINE, LETROZOLE and ABEMACICLIB (VERZENIO) for an unknown indication.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (feels like she is going to die/ does not feel well today), PYREXIA (Fever) and VOMITING (vomited). At the time of the report, VACCINATION COMPLICATION (feels like she is going to die/ does not feel well today), PYREXIA (Fever) and VOMITING (vomited) outcome was unknown.            Treatment medication was not provided by the reporter.; Sender's Comments: Based on the current available information and temporal association between the use of the product, and the start date of the events, a causal relationship cannot be excluded.
Pain, swelling (lymph gland) L collar bone area, L axillary lymph node. Enlargement, heat, swelling, redness L upper arm injection site. Painful also.
Woke up and noticed he had no feeling to one side of his face, swelling to his top lip and a weird feeling in his mouth like he had just been to the dentist.
Vasovagal Syncope 20 hours after Moderna's second dose; This spontaneous case was reported by a physician and describes the occurrence of SYNCOPE (Vasovagal Syncope 20 hours after Moderna's second dose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced SYNCOPE (Vasovagal Syncope 20 hours after Moderna's second dose). At the time of the report, SYNCOPE (Vasovagal Syncope 20 hours after Moderna's second dose) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product was not provided by the reporter.Treatment product was not provided by the reporter  Physician was  like to ask some questions about the vaccine before receiving the booster dose. HCP was scheduled to receive booster dose tomorrow  Cortisone shot (40 mg) was received on a week ago in her shoulder.  Company's comment: This case concerns a female subject of unknown age, with no relevant medical history, who experienced the unexpected event of Syncope, diagnosed as "vasovagal syncope" by the reporter(physician). The event occurred 20 hours after the second dose of mRNA 1273 VACCINE. Rechallenge is unknown as only information regarding adverse event after the second dose is available. The benefit-risk relationship of mRNA 1273 VACCINE is not affected by this report. Event Syncope was upgraded as serious as per IME list; however, based on information available and, as per medical judgement, it is assessed as non-serious, similar to reporter's assessment.; Sender's Comments: This case concerns a female subject of unknown age, with no relevant medical history, who experienced the unexpected event of Syncope, diagnosed as "vasovagal syncope" by the reporter(physician). The event occurred 20 hours after the second dose of mRNA 1273 VACCINE. Rechallenge is unknown as only information regarding adverse event after the second dose is available. The benefit-risk relationship of mRNA 1273 VACCINE is not affected by this report. Event Syncope was upgraded as serious as per IME list; however, based on information available and, as per medical judgement, it is assessed as non-serious, similar to reporter's assessment.
This spontaneous report was received from a pharmacist referring to a patient of unknown age and gender. No information about the patient's medical history, concurrent conditions, drug reactions or allergies and concomitant therapies was provided. On 18-JAN-2017 at 08:20, the patient was vaccinated with an improperly stored VARIVAX (lot # M031969) for prophylaxis (expiration date, dose and route of administration were not reported). It was reported that the vaccine underwent previous temperature excursions, but the number of previous excursions, time frames and values of incorrect temperature were unknown. A digital data logger was used. No adverse effects were reported. Product quality complaint was not involved. This is one of several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1701USA008441: US-009507513-1704USA000389: US-009507513-1704USA000390: US-009507513-1704USA000391: US-009507513-1704USA000392: US-009507513-1704USA000393: US-009507513-1704USA000394: US-009507513-1704USA000395: US-009507513-1704USA000396: US-009507513-1704USA000397: US-009507513-1704USA000398: US-009507513-1704USA000399: US-009507513-1704USA000400: US-009507513-1704USA000401: US-009507513-1704USA000402: US-009507513-1704USA000403: US-009507513-1704USA000404: US-009507513-1704USA000405: US-009507513-1704USA000406: US-009507513-1704USA000407: US-009507513-1704USA000408: US-009507513-1704USA000409: US-009507513-1704USA000410: US-009507513-1704USA000411: US-009507513-1704USA000412: US-009507513-1704USA000413: US-009507513-1704USA000414: US-009507513-1704USA000415: US-009507513-1704USA000416: US-009507513-1704USA000417: US-009507513-1704USA000418: US-009507513-1704USA000419: US-009507513-1704USA000420: US-009507513-1704USA000421: US-009507513-1704USA000422: US-009507513-1704USA000423: US-009507513-1704USA000424: US-009507513-1704USA000425: US-009507513-1704USA000426: US-009507513-1704USA000427: US-009507513-1704USA000428: US-009507513-1704USA000429: US-009507513-1704USA000430: US-009507513-1704USA000431: US-009507513-1704USA000432: US-009507513-1704USA000433: US-009507513-1704USA000434: US-009507513-1704USA000435: US-009507513-1704USA000436: US-009507513-1704USA000437: US-009507513-1704USA000438: US-009507513-1704USA000439: US-009507513-1704USA000440: US-009507513-1704USA000441: US-009507513-1704USA000443: US-009507513-1704USA000444: US-009507513-1704USA000445: US-009507513-1704USA000446: US-009507513-1704USA000447: US-009507513-1704USA000448: US-009507513-1704USA000449: US-009507513-1704USA000450: US-009507513-1704USA000451: US-009507513-1704USA000452: US-009507513-1704USA000453: US-009507513-1704USA000454: US-009507513-1704USA000455: US-009507513-1704USA000456: US-009507513-1704USA000457.
late dose/The first dose was administered before the pandemic; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 67-year-old male patient who received Herpes zoster (Shingrix) (batch number 5954H) for prophylaxis.   Previously administered products included Shingrix (first dose was administered before the pandemic).   On 24-JUL-2023, the patient received the 2nd dose of Shingrix. On 24-JUL-2023, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: late dose/The first dose was administered before the pandemic). The outcome of the drug dose administration interval too long was unknown.   Additional Information: GSK Receipt Date: 25-JUL-2023 The reporter consented to follow up via email. The patient received 2nd dose of Shingrix later than the recommended schedule, which led to lengthening of vaccination schedule.
Major stoke three days after injection.  He was unable to recover and subsequently passed away after one month.
Chills; Fever; Very Tired; This spontaneous case was reported by a consumer and describes the occurrence of CHILLS (Chills), PYREXIA (Fever) and FATIGUE (Very Tired) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 023C21A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included AMLODIPINE and METFORMIN for an unknown indication.    On 03-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-May-2021, the patient experienced CHILLS (Chills), PYREXIA (Fever) and FATIGUE (Very Tired). At the time of the report, CHILLS (Chills), PYREXIA (Fever) and FATIGUE (Very Tired) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was reported.
Runny nose. Runny watery eyes, metallic taste in mouth, sore upper arm muscles on both arms, nausea, chills, fever, body aches , headache
Severe itching on feet, ankles, lower legs, hands, wrists, forearms developed in the evening and has continued intermittently (daily, but generally in the evening and night). It is only relieved with ice packs. I had similar itching episodes following the first two vaccines and the first booster,  but I did not report them because I did  not realize they might be related to the shots.
Rash all over their body; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of RASH (Rash all over their body) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Feb-2021, the patient experienced RASH (Rash all over their body). At the time of the report, RASH (Rash all over their body) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not reported.  Treatment for the event included steroid injection.
Irregular heart beat that lasted about 14 hours....elevated blood pressure that reached 181/108...took my Amlodipine when I got home and then the blood pressure fell to 110/74...after a couple hours the pressure returned to normal 123/75. Did not go to hospital..kept thinking it would go away and after many hours it did.
This spontaneous report was received from an unspecified healthcare worker from a pharmacy via a company representative concerning two patients of unknown age and gender. On an unknown date, patients were vaccinated with a dose of ZOSTAVAX (lot number reported as J00444, expiry date, dose and route unspecified). No concomitant medications were reported. On an unknown date, the patients experienced unspecified adverse experience. Patients sought medical attention (both the patients were hospitalized with an unspecified length of stay at an unspecified hospital). It was unspecified if any treatment was given or if any lab tests were performed. The outcome of unspecified adverse experience was unknown. The relatedness for unspecified adverse experience was unknown for ZOSTAVAX. Additional information has been requested.
Patient was wanting to receive 2nd dose of Moderna primary series during office visit. I went into the fridge where all vaccines are stored, and seen 1 vial of primary Moderna series with a written expiration date "2/24/2023" on the cap. After reviewing the pre- vaccination questions with patient, patient was okay to receive vaccine. I went into the vaccine preparation area, and drew up 0.50 ml of the Moderna vaccine, and administered to patient in right deltoid. After administering vaccine, and went to document vaccine in patient's record, the lot number 057A22A was not appearing in system due to expiring 1 year after manufacturing date. Patient waited the routine 15 minutes after administration of the vaccine, with no side effects or complaints, and went home.
Arm hurts like absolute crap, cannot move it without pain. Fever of 100.2. Feel weird.
numbness in lips, BP 160/92, P110, rash, urticaria, SOB, dysphagia;
Very sore arm at the injection site as well as about 3 inches below. It was also sensitive to the touch. Symptoms dissolved by day 2.
Swelling at site of injection; tender at site of injection; headache; Hot at site of injection; Itching at site of injection; heat and pain even radiated up my neck toward my right ear; Injection site erythema; This spontaneous case was reported by a consumer and describes the occurrence of NECK PAIN (heat and pain even radiated up my neck toward my right ear), VACCINATION SITE WARMTH (Hot at site of injection), VACCINATION SITE PRURITUS (Itching at site of injection), VACCINATION SITE SWELLING (Swelling at site of injection) and VACCINATION SITE LYMPHADENOPATHY (tender at site of injection) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 006M20A and 010A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Penicillin allergy, Drug allergy (erythromycin) and Drug allergy (sulfa drugs). Concomitant products included FLUTICASONE PROPIONATE (FLONASE ALLERGY RELIEF) for an unknown indication.   On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 19-Feb-2021, the patient experienced NECK PAIN (heat and pain even radiated up my neck toward my right ear) and VACCINATION SITE ERYTHEMA (Injection site erythema). On 20-Feb-2021, the patient experienced VACCINATION SITE PRURITUS (Itching at site of injection). On 21-Feb-2021, the patient experienced VACCINATION SITE WARMTH (Hot at site of injection), VACCINATION SITE SWELLING (Swelling at site of injection), VACCINATION SITE LYMPHADENOPATHY (tender at site of injection) and HEADACHE (headache). On 21-Feb-2021, HEADACHE (headache) had resolved. On 25-Feb-2021, VACCINATION SITE WARMTH (Hot at site of injection), VACCINATION SITE PRURITUS (Itching at site of injection), VACCINATION SITE SWELLING (Swelling at site of injection) and VACCINATION SITE LYMPHADENOPATHY (tender at site of injection) had resolved. At the time of the report, NECK PAIN (heat and pain even radiated up my neck toward my right ear) and VACCINATION SITE ERYTHEMA (Injection site erythema) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) and mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications were not provided.  Action taken with the drug in response to the events was not applicable.   Most recent FOLLOW-UP information incorporated above includes: On 11-May-2021: Two events were added and second dose information was added
VACCINE WAS REFROZEN; REFROZEN VACCINE WAS ADMINISTERED TO PATIENT; This spontaneous report received from a health care professional concerned a 63 year old female. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1821286 expiry: 20-MAR-2022) dose was not reported, administered on 08-SEP-2021 for prophylactic vaccination. No concomitant medications were reported.  On an unspecified date, the patient experienced vaccine was refrozen, and refrozen vaccine was administered to patient. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the vaccine was refrozen and refrozen vaccine was administered to patient was not reported. This report was non-serious. This case, from the same reporter is linked to 20220538292, 20220537341, 20220537356, 20220537444, 20220537507, 20220537548, 20220538146, 20220538210, 20220538297, 20220538379, 20220538480, 20220538890, 20220539045, 20220540324, 2005084289, 20220540611, 20220537688, 20220537683, 20220538238, 20220538316, 20220538425, 20220538428, 20220538437, 20220538573, 20220538627, 20220538666 and 20220538758.
Myalgia, Arthralgia, Diarrhea, chills, fatigue Narrative:
Developed a rash on both arms, legs, hands, and feet. Denies itching or pain. Denies any other symptoms. Went to her PCP 1 week after vaccination. No treatment given. She has not taken any medication for the rash. The rash continues to this day, 01/14/2022.
Large erythematous area to right posterior upper arm. Measures app 6 x 7 inches in diameter, warm to touch, tender but non-fluctuant, no masses present.
pt presents to hosp via EMS; O2 sats 85% on RA in the field; pt with cough and SOB x 1 wk; positive for COVID; monoclonal antibodies; Vapotherm 40L/80% but still having frequent desaturation requiring proning; dexamethasone, remdesivir, baricitinib, ABX, DVT prophylaxis; Klebsiella pneumonia; pt's condition continued to decline requiring intubation; worsening condition and was transitioned to comfort care, pt died in the hospital
Rash on both sides of body; itchy, pink, raised with no vesicles.